FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
16.0 pts (24h)GéopolitiqueOne-OffHealth & Medicine3mois
KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
Oui 98%+16.0pt
Qualité du marché
44 / 100
Faible qualitéVolume 24h
510,9 €
Liquidité
156,6 €
Faible liquiditéAchat / Vente
80.0% / 88.0%
Écart
8.0 pt
Spread largeDonnées du marché
Mis à jour il y a 7 minutes
17 juin 26, 21:00 UTC1 janv. 27, 04:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
KalshiDid COVID-19 come from a laboratory?
Manifold MarketsWhich states will report local cases in the May 2026 Ebola Bundibugyo outbreak
Manifold MarketsWhen, where or how will Trump die?
Manifold MarketsRègles
If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Règlement via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Ifinatamab deruxtecan (also called I-DXd or DS-7300) is an antibody-drug conjugate — think of it as a guided missile where a targeting protein is chemically linked to a potent cancer-killing payload.
- The targeting protein homes in on a molecule called B7-H3 (also known as CD276), which appears in unusually high amounts on the surface of many cancer cells, and once the drug locks onto that target it is pulled inside the cell and releases its toxic payload.
- In doing so, it aims to kill tumor cells more precisely than traditional chemotherapy, which attacks both healthy and cancerous cells indiscriminately.
Marchés ouverts
Geopolitics
POLYMARKETWhich party will gain most seats in Russian Parliamentary Election?
- United Russia (ER)+5.0pt75%
- New People (NL)-4.1pt21%
- Liberal Democratic Party of Russia (LDPR)-1.1pt3%
+5 résultats de plus
- Volume total
- 22,2 M €
- Volume 24h
- 470,8 k €
POLYMARKETUS announces end of Iranian blockade by which date?
- December 31-2.3pt48.3%
- October 31-2.0pt29.3%
- September 30-4.0pt12.1%
+17 résultats de plus
POLYMARKETUS x Iran Effective Ceasefire begins by...? (2 week pause)
- September 30+1.0pt80%
- September 18+1.0pt75%
- September 11+6.5pt70%
+2 résultats de plus
POLYMARKETWill China invade Taiwan by end of 2026?
- No-0.2pt96%
- Yes+0.2pt4%
- Volume total
- 35,3 M €
- Volume 24h
- 100,1 k €
POLYMARKETIsrael x Iran ceasefire continues through which date?
- July 18+0.3pt100%
- July 20+0.1pt100%
- July 22+0.5pt100%
+20 résultats de plus
POLYMARKETKharg Island no longer under Iranian control by which date?
- December 317%
- September 30+0.1pt1%
- July 310%
+7 résultats de plus
- Volume total
- Nobel Peace Prize Winner 2026
- US-Iran nuclear deal?
- Russia x Ukraine peace talks by which date?
- Strait of Hormuz traffic returns to normal by December 31?
- Will the U.S. invade Iran before 2027?
- Bab el-Mandeb Strait effectively closed by which date?
- What will Trump say during RNC Convention (Night 2)?
- Russia x Ukraine ceasefire agreement by which date?
- Iran-Oman Hormuz Management Agreement by which date?
- Will the Iranian regime fall by September 30?
Questions fréquentes
- Quelles sont les probabilités actuelles pour FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) ?
- Kalshi cote Yes à 98% au 8 septembre 2026.
- Quand FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) sera-t-il résolu ?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) doit être résolu le 1 janvier 2027.
- Comment FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) est-il réglé ?
- Kalshi règle ce marché comme suit : If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.